MPN Research: A Legacy of Caring
MPN research has come a long way since 1951 when William Dameshek first described the concept of myeloproliferative disorders. Since then, at the urging of patients and through the tireless efforts of caring advocates like the MPN Research Foundation, great strides have been made in our understanding of these disorders and in the development of new treatment options for MPNs.
The MPN Research Foundation has played an important role in advancing research and treatment options for MPN patients. Important milestones in the history of MPN research include:
- 1999: The first clinical trial for myeloproliferative disorders, “Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders” is initiated.
- 2003: The MPD Research Consortium is created to serve as a multi-institution, international group dedicated to establishing clinical trials and conducting basic research into new therapies and treatments.
- 2005: The JAK2V617F mutation is discovered. JAK2 is the first known genetic mutation associated with myeloproliferative diseases.
- 2008: Myeloproliferative disorders are reclassified as myeloproliferative neoplasms (MPNs) by the World Health Organization and nested within the blood cancer category.
- 2011: The first FDA-approved treatment for myelofibrosis, Jakafi, is released.
- 2013: Calreticulin (CALR) is discovered – a second significant genetic mutation that accounts for the majority of JAK2 negative patients.
Creating a Better Future Together
Developments in MPN research have resulted in more and better treatment options for MPN patients, many of whom live for decades with PV, ET and even MF. Since 2000, the MPN Research Foundation has been a committed partner to MPN patients and their families by advocating for and funding further advances in research.
Sign up to receive regular updates on the latest MPN research and join us in our efforts to change the prognosis for MPN patients and their families.